Literature DB >> 11493098

Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial.

M A Weinstock1, S F Bingham, G W Cole, D Eilers, M F Naylor, J Kalivas, J R Taylor, H B Gladstone, D J Piacquadio, J J DiGiovanna.   

Abstract

OBJECTIVE: To assess the reliability of counts of actinic keratoses (AKs) and the effect of a brief joint discussion of discrepancies on that reliability. DESIGN AND INTERVENTION: Seven dermatologists independently counted AKs on the face and ears before and after a brief joint discussion of discrepancies. SETTING AND PATIENTS: A volunteer sample of 9 patients from the ongoing VA (Department of Veterans Affairs) Topical Tretinoin Chemoprevention (VATTC) Trial. All participating individuals are veterans and have had 2 or more keratinocyte carcinomas (basal or squamous cell carcinoma) in the 5 years before enrollment in the study. MAIN OUTCOME MEASURE: Standard deviation of estimates of the Poisson regression parameter for the dermatologists.
RESULTS: Substantial variation was found among the dermatologists in their AK counts. The SD of the parameter estimates for the dermatologists decreased from 0.45 to 0.24 after the brief joint discussion, a 47% decrease (P =.076). The variation attributable to the dermatologists also decreased substantially (chi(2)(6) decrease, 94 to 12).
CONCLUSIONS: Actinic keratoses are common, and there is a continuous spectrum of lesions that ranges from sun-damaged skin to squamous cell carcinoma in situ. Clinical distinguishing features may be difficult to delineate precisely. Counts of AK are commonly performed, but appear to be unreliable, even when performed by experienced dermatologists. Joint discussion of discrepancies may enhance the reliability of these counts, although substantial variation remains. Research that relied on these counts must be reevaluated in light of the marked variation among expert observers. Future studies should consider measures to assess and enhance reliability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493098

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

1.  Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).

Authors:  Melody J Eide; Martin A Weinstock; Raymond G Dufresne; Suleka Neelagaru; Patricia Risica; Gary J Burkholder; David Upegui; Katharine A Phillips; Bruce K Armstrong; Leslie Robinson-Bostom
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

2.  An update on nonmelanoma skin cancer.

Authors:  Rita V Patel; Amylynne Frankel; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2011-02

Review 3.  Retinoids for prevention and treatment of actinic keratosis.

Authors:  Mayra Ianhez; Luiz Fernando Fróes Fleury; Hélio Amante Miot; Edileia Bagatin
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

4.  Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.

Authors:  David D Dore; Kate L Lapane; Amal N Trivedi; Vincent Mor; Martin A Weinstock
Journal:  Ann Intern Med       Date:  2009-01-06       Impact factor: 25.391

5.  Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Authors:  Craig A Elmets; Jaye L Viner; Alice P Pentland; Wendy Cantrell; Hui-Yi Lin; Howard Bailey; Sewon Kang; Kenneth G Linden; Michael Heffernan; Madeleine Duvic; Ellen Richmond; Boni E Elewski; Asad Umar; Walter Bell; Gary B Gordon
Journal:  J Natl Cancer Inst       Date:  2010-11-29       Impact factor: 13.506

6.  Automated detection of actinic keratoses in clinical photographs.

Authors:  Samuel C Hames; Sudipta Sinnya; Jean-Marie Tan; Conrad Morze; Azadeh Sahebian; H Peter Soyer; Tarl W Prow
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

7.  Method of Assessing Skin Cancerization and KeratosesTM (MASCK™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization.

Authors:  Christopher Baker; Amelia James; Madeleine Supranowicz; Lynda Spelman; Stephen Shumack; Judith Cole; Warren Weightman; Robert Sinclair; Peter Foley
Journal:  Clin Exp Dermatol       Date:  2022-03-22       Impact factor: 4.481

8.  Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).

Authors:  Zeeshaan-Ul Hasan; Ikhlaaq Ahmed; Rubeta N Matin; Victoria Homer; John T Lear; Ferina Ismail; Tristan Whitmarsh; Adele C Green; Jason Thomson; Alan Milligan; Sarah Hogan; Vanessa Van-de-Velde; Liza Mitchell-Worsford; Jonathan Kentley; Claire Gaunt; Yolande Jefferson-Hulme; Sarah J Bowden; Piers Gaunt; Keith Wheatley; Charlotte M Proby; Catherine A Harwood
Journal:  Br J Dermatol       Date:  2022-06-14       Impact factor: 11.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.